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Abstract Treatment of malignant disease is of paramount
importance in modern medicine. In 2012, it was estimated that
162,000 people died from cancer in the UKwhich illustrates a
fundamental problem. Traditional treatments for cancer have
various drawbacks, and this creates a considerable need for
specific, molecular targets to overcome cancer spread. Epithe-
lial protein lost in neoplasm (EPLIN) is an actin-associated
molecule which has been implicated in the development and
progression of various cancers including breast, prostate, oe-
sophageal and lungwhere EPLIN expression is frequently lost
as the cancer progresses. EPLIN is important in the regulation
of actin dynamics and has multiple associations at epithelial
cells junctions. Thus, EPLIN loss in cancer may have signif-
icant effects on cancer cell migration and invasion, increasing
metastatic potential. Overexpression of EPLIN has proved to
be an effective tool for manipulating cancerous traits such as
reducing cell growth and cell motility and rendering cells less
invasive illustrating the therapeutic potential of EPLIN. Here,
we review the current state of knowledge of EPLIN, highlight-
ing EPLIN involvement in regulating cytoskeletal dynamics,
signalling pathways and implications in cancer andmetastasis.
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1 Introduction
The incidence of cancer is slowly rising and has become a
global burden. A fundamental reason why cancer is such a
problem is because of its ability to spread, invade surrounding
tissue and potentially form secondary cancers at distinct sites
around the body by metastasis. Cancer hallmarks include un-
controlled cell growth and evasion of cell death, and this ulti-
mately can lead to tumour formation. According to the World
Health Organisation (WHO), 8.2 million people died from
cancer in 2012 worldwide [1]. In the UK alone, mortality rates
reached 162,000 annual deaths [2]. This illustrates a consid-
erable need for better treatment, diagnosis and management of
the disease. Epithelial protein lost in neoplasm (EPLIN) is a
molecule involved in regulation of the actin cytoskeleton and
has been implicated in the development and progression of
various cancer types, displaying frequent downregulation or
loss in cancer, creating a potential for prognostic targeting and
as a tumour suppressor. This current review discusses
EPLIN’s role in actin dynamics and in the pathophysiology
of cancer development and progression.
2 Epithelial protein lost in neoplasm
EPLIN is a cytoskeletal, actin-binding protein encoded by the
LIMA1 gene. EPLIN was initially identified in oral cancers for
its differential expression between normal oral epithelial cells
and human papilloma virus (HPV)-immortalised oral epithe-
lial cells [3]. EPLIN exists as two distinct isoforms, a 600
amino acid EPLINα isoform and a larger 759 amino acid
EPLINβ isoform, generated from an alternative pre-mRNA
splicing event (see Fig. 1) [4]. The EPLINα isoform has been
implicated in the progression of various cancers, and this was
initially recognised in oral cancer, breast, prostate and
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xenograft tumours where EPLIN expression was either down-
regulated or completely abolished [4]. The amino acid se-
quence of EPLIN is characterised by a single centrally located
LIM domain which supposedly aids structural self-
dimerisation and contains subdomains for zinc binding (see
Fig. 2) [4, 5]. LIM-domain-containing proteins are frequently
present in molecules responsible for cytoskeletal organisation,
such as the focal adhesion phosphoprotein, paxillin [6].
EPLIN is important in the regulation of actin dynamics and
aids actin filament bundle assembly, and the amino terminal of
the EPLIN protein structure is essential for this localisation to
the actin cytoskeleton [7]. The EPLIN genomic structure con-
sists of 11 exons and ten introns, with exons 1–3 only present
in EPLINβ and EPLINα utilising exons 4–11 of LIMA1 for
transcription [5]. The EPLIN gene has two separate promoter
regions; the EPLINβ promoter is near the start of the gene in
exon 1, whilst EPLINα initiates ∼50 kb downstream near the
end of intron 3, prior to exon 4 and at amino acid position 161
in the EPLINβ protein (see Fig. 1) [5]. Sequence analysis has
revealed that EPLIN is conserved across species with EPLINα
and EPLINβ isoforms present in mouse, displaying 77 and
75 % identity similarity for human EPLINα and EPLINβ,
respectively (see Fig. 3) [8]. A role for EPLIN has also been
suggested in muscle development in pigs, where EPLIN
displayed a temporal expression pattern with only the
EPLINα isoform present in developing skeletal muscle [9].
Since the discovery of EPLIN, our lab has shown that aberrant
EPLIN expression is associated with the progression of
various cancer types including breast, oesophageal, pulmo-
nary and prostate cancer. EPLINα levels decrease as the can-
cer progresses and becomes more advanced, giving EPLINα
potential to provide prognostic value, and overexpression
analysis suggests that EPLINα is a putative tumour suppres-
sor [10–14]. The described loss of EPLIN in cancer has func-
tional implications on the actin cytoskeleton and may contrib-
ute to enhanced metastatic potential of cancer cells.
2.1 The epithelial protein lost in neoplasm interactome:
regulation in actin dynamics
EPLIN has a number of functional partners (see Fig. 4/
Table 1), and the globular protein actin is central to the func-
tion of EPLIN. EPLIN has two functional actin-binding sites
which flank the central LIM domain, and it is this binding
capacity that engenders actin cross linking and actin filament
bundle assembly [15]. A fibrillar pattern is displayed by both
isoforms, and expression of EPLINα enhances the size and
number of actin filament stress fibres and can also inhibit
membrane ruffling via the signalling GTPase, Rac1 [15].
EPLIN therefore directly interacts with actin which suggests
a possible role for EPLIN in cell migration, adhesion and cell
morphology. Actin is an abundant, multifunctional protein
responsible for cell migration in eukaryotic cells. Actin is part
of the cytoskeletal network which consists of microtubules,
microfilaments and intermediate filaments which are vital for
cellular functions. Actin exists as monomers (G-actin) and
Fig. 1 Schematic diagram of the LIMA1 genomic structure and EPLIN
structural isoforms. The LIMA1 gene consists of 11 exons and ten introns.
EPLINα differs from EPLINβ at the amino terminus where an additional
160 amino acids are present in EPLINβ. Shown below EPLINβ is the 52-
amino acid centrally located LIM domain common to both EPLIN iso-
forms. Adapted from [4]
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filamentous polymers (F-actin) and is important for physio-
logical functions including cell locomotion, cytokinesis,
maintenance of cell shape and muscle contraction [24]. Tran-
scription of the LIMA1 gene is suggested to be primarily con-
trolled by monomeric G actin, with the actin–MAL–SRF sig-
nalling pathway regulating EPLIN production [25].Maul et al.
[15] illustrated that EPLINα has three significant features:
EPLINα has at least one binding site for actin and can cross
link and bundle actin filaments, EPLINα stabilises actin fila-
ments in vitro, and EPLINα inhibits branching nucleation of
actin filaments by the Arp 2/3 complex [15]. Therefore, this
suggests that EPLIN may orchestrate actin filament dynamics
by stabilising actin cytoskeletal networks [15]. Additionally,
EPLIN has been shown to form part of an actin-remodelling
complex composing of EPLIN, β-actin, γ-actin and gelsolin
which co-localises at the plasma membrane to the tumour
suppressor, phosphatase and tensin homolog (PTEN) [26].
PTEN is a well-established tumour suppressor molecule, so
this asks the question of whether the interaction of PTEN and
the actin-remodelling complex is itself an element suppressing
the development of neoplastic tissue and whether any inter-
ruption of these complexes may promote cancer progression.
Based on these findings, EPLIN accommodates actin to ac-
complish various actin-related cellular processes including
cell motility and migration and cell junctional adhesion [17].
There is increasing evidence to suggest that EPLIN regulates
actin structures in cooperation with the signal transduction
adaptor protein, paxillin. When EPLIN is overexpressed,
paxillin exhibits an increased staining pattern for both human
endothelial cells line (HECV) and PC-3 cells [12, 13]. This co-
localisation pattern is also observed in cultured human
mesangial cel ls at focal adhesion si tes , and co-
immunoprecipitation results confirm an association between
the two molecules [16]. EPLIN and paxillin may form a com-
plex and potentially stabilise focal adhesions to co-ordinate actin
dynamics in a complimentary manner. Given EPLIN’s role in
actin dynamics, it is strongly implicated in cellular processes
including cell migration and invasion, and thus, downregulation
or loss of EPLIN expression in cancer may likely affect the
metastatic potential of cancer cells. Actin and EPLIN are located
in epithelial cells at the adherens junction (AJ) and contribute to
functional cellular adhesion between adjacent cells.
2.2 The adherens junction
The AJ is a type of anchoring junction found predominantly in
epithelial cells, also referred to as the zonula adherens, which
functionally link the actin cytoskeleton together in cells via
Fig. 2 Protein structure of EPLIN LIM domain (PDB ID=2D8Y).
Protein structure of the EPLIN centrally located LIM domain. Zinc-
binding domains depicted. This domain may aid self-dimerisation. Image
generated using UCSF Chimera software
Fig. 3 ClustalW protein alignment of human, mouse and pig EPLINβ.
Areas of amino acids that are conserved across species are highlighted.
The region shown is amino side of the EPLINβ protein, where EPLINα
originates at amino acid (AA) p. 161. ClustalW generated using BioEdit
Biological Sequence Alignment software
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linker molecules. EPLIN is an actin-binding protein, which
functions to bundle actin filaments; therefore, EPLIN pres-
ence is required at AJ along with filamentous actin. AJ con-
tains various protein complexes along with EPLIN, and these
include cadherins, catenins and p120 catenins (see Fig. 5)
[28]. Within the AJ, cadherins and catenins associate together
to form the cadherin–catenin complex and EPLIN provides a
direct physical link for this complex to the actin cytoskeleton
[17]. The cadherin–catenin complex is composed of E-
cadherin,β-catenin andα-catenin, with E-cadherin positioned
between adjacent cells and the catenins positioned in the cy-
toplasmic space of each cell [29]. E-cadherin binds directly to
β-catenin which sequentially binds α-catenin, generating the
cadherin–catenin complex (see Fig. 5) [30]. α-Catenin is a
crucial player at the AJ and was initially recognised as respon-
sible for providing the bridge between the cadherin–catenin
Fig. 4 EPLIN predicted functional partners. EPLIN (LIMA1) has vari-
ous associations including cadherin and catenin molecules which contrib-
ute to cytoskeleton regulation. LIMA1 LIM domain and actin binding 1;
CDH1 cadherin 1; CTNNA1 catenin-α1; CDH1 cadherin 1; CTNND1
catenin-δ1; CTNNB1 catenin-β1; UBC ubiquitin C; PTPLAD1 protein
tyrosine phosphatase-like A domain-containing 1; ARPC1A actin-
related protein 2/3 complex, subunit 1A; ATP6V1B1 ATPase, H+
transporting, lysosomal 56–58 kDa, V1 subunit B1; YWHAH tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation protein;
SVIL supervillin. Image generated and extracted from online STRING
database
Table 1 EPLIN-associated molecules
EPLIN
association
Biological significance and reference References
Actin Actin is an abundant protein important for cell migration. EPLIN has two actin-binding domains that flank the EPLIN LIM
domain. Pull-down assays revealed that EPLIN binds actin monomers, and this results in actin cross linking and actin
filament bundle assembly.
[15]
Paxillin May form a complex with EPLIN to co-ordinate actin dynamics. IHC of PCa tissue vs normal reveals that EPLIN
overexpression influences paxillin expression and localisation. Co-localisation, co-precipitation and an in situ proximal
ligation assay revealed direct association between the two molecules in cultured human mesangial cells.
[12, 13,
16]
α-Catenin Immunoprecipitation and GST pull-down assays reveal that EPLIN interacts with α-catenin, forming a cadherin–β-
catenin–α-catenin–EPLIN complex.
[17]
Supervillin In vivo co-localisation studies and in vitro GST pull-down assays reveal that EPLIN interacts with the peripheral
membrane protein, supervillain.
[18]
PINCH-1 Pull-down assays reveal that endogenous EPLIN co-immunoprecipitates with endogenous PINCH-1 in keratinocytes. [19]
ERK ERK phosphorylates EPLIN and decreases EPLIN affinity to F-actin promoting cell migration. Inhibition of ERK
abolishes EPLIN expression and reduces tumour-suppressive ability of EPLIN.
[10, 13,
20]
DNp73 In melanoma cells, both EPLIN isoforms are inhibited by DNp73, and this drives a more invasive phenotype. [21]
SATB2 EPLIN is differentially regulated by the DNA-binding protein, SATB2. SATB2 regulates the actin cytoskeleton via EPLIN
association. When SATB2 is knocked out, osteosarcoma cells show reduced migration and are less invasive, and this is
mediated by EPLIN.
[22]
Cav-1 EPLIN regulates the lipid raft tumour-suppressive protein, Cav-1. Co-immunoprecipitation and mass spectroscopy anal-
ysis revealed that EPLIN and Cav-1 bind to each other in normal and RasV12 cells.
[23]
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complex and actin [28, 31]. This principle, however, has come
under scrutiny, as direct in vitro binding between α-catenin
and actin has never been detected [32, 33]. Cavey and co-
workers [34] realised that α-catenin is not essential for E-
cadherin stability, as complexes of α-catenin and E-cadherin
were detected in RNAi α-catenin embryos [31]. Therefore, it
is apparent that cadherin–actin interaction is regulated not
only by α-catenin but by a number of actin-binding proteins
that are associated with α-catenin, including EPLIN [30, 35].
Abe and Takeichi [17] demonstrated, by immunoprecipitation
and GST pull-down assays, that both EPLIN isoforms directly
interact with the α-catenin VH3 plus C-terminal region to
generate a cadherin–catenin–EPLIN–actin complex at cell
junctions [17]. When EPLIN is depleted, the bridge to F-
actin was unable to form due to loss of organisation of the
apical actin belt, with punctate accumulation of E-cadherin at
cell junctional points [17]. This illustrates the importance of
EPLIN in producing functional epithelial junctions. Addition-
al molecules involved in regulating the AJ include the mem-
brane cytoskeletal protein, vinculin, and the actin filament-
binding protein, afadin [36, 37]. Recent work from Taguchi
et al. [35] illustrated that EPLIN and vinculin may collaborate
together in AJ formation via binding α-catenin either together
or individually and cooperatively aid junctional adhesion [35].
The cooperation of EPLIN and vinculin in cellular adhesion is
also evident in endothelial cells. At the endothelial AJ, the
endothelial E-cadherin homolog, VE-cadherin, interacts with
β- and γ-catenins, which sequentially bind α-catenin and
EPLIN in an analogous fashion to epithelial cells [38]. This
allows the recruitment of vinculin and ultimately promotes
strengthening of inter-endothelial junctions [38]. The authors
propose a role for EPLIN in tension dissemination at the en-
dothelial AJ in a mechanosensory mechanism [38]. The ma-
chinery from actomyosin exerts tension through EPLIN,
which causes α-catenin to adopt a more accessible conforma-
tion, revealing a vinculin-binding site and allowing vinculin
recruitment and actin association at endothelial cell–cell AJ
[39]. This mechanotransduction mechanism consisting of
EPLIN and α-catenin suggests that the endothelial AJ is reg-
ulated in a spatial and temporal fashion [39]. Finally, EPLIN
also appears to be important for attachment to F-actin in en-
dothelial cells; when EPLIN expression is downregulated, the
organisation of F-actin is considerably disrupted, leading to
multiple holes in the actin cytoskeleton [38]. Altogether, this
suggests that the AJs of epithelial and endothelial cells are
orchestrated by various actin-binding, α-catenin-associated
molecules and are dynamically regulated, with EPLIN having
a critical role in cell adhesion, creating further implications of
EPLIN loss in cancer.
2.3 Epithelial protein lost in neoplasm—a key player
in cell division?
Cell division is the splitting of one cell into two, where bio-
logical information is passed onto daughter cells. For this
process to successfully occur, various proteins need to func-
tionally regulate the division and these include Rho GTPases,
cyclin-dependant kinases, integrins, cdc42, focal adhesion
Fig. 5 Schematic representation of adherens junctions. The AJ between
epithelial cells consists of various protein complexes to orchestrate actin
cytoskeletal dynamics. The cadherin–catenin complex is associated with
filamentous actin via EPLIN and/or vinculin which binds α-catenin in the
cytoplasm. Adapted from [27]
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kinases, myosin and the globular protein actin [40]. With this
in mind, an actin-binding protein like EPLIN may potentially
have a regulatory role in cell division. This has been recently
shown using HeLa cells where EPLIN depletion resulted in
large numbers of multinucleated cells, signifying cytokinesis
failure during cell division [41]. In successful mitotic division,
actin and myosin II accumulate at the cleavage furrow during
cytokinesis and EPLIN loss compromised each protein’s abil-
ity to efficiently do this [41]. EPLIN appears to be important
for the accumulation of other mitotic regulatory proteins in-
cluding the GTPases RhoA and cdc42, where EPLIN deple-
tion resulted in either a significantly reduced concentration of
RhoA or a misplaced location of cdc42 at the cleavage furrow
[41]. EPLIN aids this successful cell division in conjunction
with a number of regulatory proteins including supervillin and
the oncogenic kinesin, KIF14, suggesting a complex network
of regulatory proteins at the cleavage furrow [18]. Altogether,
this suggests that EPLIN may have an integral role in cytoki-
nesis and loss may lead to aneuploidy and genomic instability
of daughter cells [41]. Therefore, EPLIN is crucial to co-
ordinate actin and myosin dynamics throughout cell division
and loss in cancer cells could have downstream effects on
successful cytokinesis, increasing their tendency to form a
cancer [41].
2.4 Post-translational modification
Extracellular signal-regulated kinase (ERK) is a member of
the mitogen-activated protein kinase (MAPK) family and is
important in the regulation of actin organisation by phosphor-
ylating various proteins including paxillin, focal adhesion ki-
nase (FAK) and other protein kinases and nuclear transcription
factors to co-ordinate cellular processes [42, 43]. ERK is im-
plicated in cellular events including cell migration and may
facilitate this by phosphorylation of actin-bundling proteins
like EPLIN [20]. The protein structure of EPLIN has multiple
putative phosphorylation sites (see Fig. 6), and it has been
shown that ERK phosphorylates EPLIN at Ser360, Ser602
and Ser692 in vitro and in vivo [20]. Phosphorylation at the
carboxy terminal of EPLIN decreases affinity to F-actin and
thus provokes a reorganisation of the actin cytoskeleton, en-
hancing cell migration [20]. This implicates ERK in actin
organisation and cell motility with EPLIN being a critical
substrate for phosphorylation [20]. A recent study by Zhang
et al. [44] illustrated that this ERK-mediated phosphorylation
of EPLIN is itself regulated by epidermal growth factor (EGF)
and revealed how targeting this signalling cascade can be ma-
nipulated to reduce epithelial–mesenchymal transition (EMT)
and, thus, prostate cancer invasiveness [44]. ERK also plays a
role in targeting EPLIN to focal adhesions and effects the
interaction with paxillin; activation of the MEK–ERK path-
way both reduced localisation of EPLIN to sites of focal ad-
hesions and abolished paxillin interaction [16]. These data
suggest that ERK is functionally related to EPLIN and pro-
vides a critical regulatory role for appropriate actin dynamics
and may have implications in cancer progression.
3 The role of epithelial protein lost in neoplasm
in cancer
Cancer progression involves various cellular, morphological
and molecular alterations which result in a transformed cellular
phenotype, ultimately having the potential to invade surround-
ing tissue and disseminate throughout the body. Cancer treat-
ment options remain largely unspecific and create various un-
desired side effects. Therefore, elucidating a molecular target
for treating cancer, in addition to understanding the mechanism
of cancer development, is crucial. EPLIN first received atten-
tion for its involvement in cancer in 1999 where EPLIN down-
regulation was described in various cancer cell lines [4]. Alto-
gether, low levels of EPLIN transcript were found in 8/8 oral
cancer cell lines, 5/6 breast cancer cell lines and 4/4 prostate
cancer cell lines [4]. Using PC-3 and DU-145 prostate cancer
cell lines, EPLIN expression was significantly reduced com-
pared to primary prostate epithelial cells (PrEC), whereas the
prostate specific antigen (PSA) positive LNCaP and LAPC4
prostate cancer cell lines failed to express EPLINα at all [4].
This notion of EPLIN loss is also seen in breast cancer where
EPLIN expression in cell lines BT-20, SKBr-3, MCF-7, T-47D
and MDA-MB-231 was either reduced or completely lost [4].
Lastly, the authors demonstrated EPLIN as a putative tumour
suppressor molecule, where overexpression of EPLINα caused
a reduction in cancer cell growth [4]. Interestingly, when
EPLINα was depleted in breast cancer cell lines, EPLINβ ei-
ther remained consistent or actually increased [4]. This illus-
trates the potential cancer protective effects that the EPLINα
isoform may exert in various cancer cell systems. EPLIN over-
expression has also proved effective in altering the growth phe-
notype and morphology in additional cell systems including
anchorage-independent NIH3T3 transformed cells [7]. Using
a soft agar assay and utilising the activated Cdc42 or the chi-
meric nuclear oncogene EWS/Fli-1 to transform NIH3T3 cells,
EPLIN overexpression resulted in a ∼80 % decrease in colony
formation for Cdc42 transformed cells, with a similar growth
decrease in EWS/Fli-1 transformed cells [7]. Interestingly,
EPLIN displayed heterogeneous staining throughout Ras cells
rather than localisation to the actin cytoskeleton [7]. This im-
plies that oncogenic transformation affects the EPLIN/actin ar-
chitecture, and thus, the localisation of EPLIN to the actin cy-
toskeleton may be important to exert its suppressive ability [7].
3.1 Prostate cancer
There is increasing evidence to suggest that EPLIN is impli-
cated in the development of prostate cancer and the process of
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EMT. EMT is a process where polarised epithelial cells are
downregulated and subjected to biochemical and morpholog-
ical changes. Epithelial cells can become transformed to a
mesenchymal cell phenotype, losing their cell polarity and cell
adhesion at cellular junctions [45]. The converted mesenchy-
mal cell phenotype has a reorganised cytoskeleton and expe-
riences alterations in cell signalling which engenders en-
hanced migratory and invasiveness capabilities and increased
resistance to apoptosis [45, 46]. During these cellular changes,
the actin molecular architecture is disrupted and protein com-
plexes like the cadherin–catenin complex and epithelial
markers are lost [47]. EPLIN is associated with the
cadherin–catenin complex and contributes to functional cyto-
skeletal dynamics [17]. Zhang and co-workers [47] used bio-
chemical and functional approaches to demonstrate that
EPLIN is a negative regulator of EMT and invasiveness in
prostate cancer (PCa) cells. EPLIN was significantly de-
creased in cells of more mesenchymal morphology (known
as the androgen refractory cancer of the prostate (ARCaPM)
cell lineage model), suggesting that EPLIN downregulation is
directly implicated in EMT, along with the cadherin–catenin
complex [47]. Depletion of EPLIN also provokes various
Fig. 7 EPLIN profile in clinical prostate and breast cancer.
Immunohistochemical staining (×20 objective magnification) of normal
and cancerous a prostate and b breast clinical samples demonstrating
EPLIN localisation and expressional differences. c, d Semi-quantitative
analysis of EPLIN staining within prostate clinical cohort demonstrates
that lower levels of EPLIN staining are associated with cancerous and
higher-grade samples. e Within a clinical breast cancer cohort, lower
transcript expression of EPLIN is seen in tumour samples compared to
normal breast tissue and was associated with a higher grade (f), a poorer
patient prognosis (g) and reduced overall survival rates (h).
Figure modified from [10, 12]
Fig. 6 Predicted phosphorylation sites in EPLINα. The protein structure
of human EPLIN has multiple putative phosphorylation sites at all
regions of the protein, including various sites where serine kinases
would likely act. Predicted threonine and tyrosine phosphorylation sites
not shown. The phosphorylated residue suggested in [20] is indicated.
Phosphorylation status predicted using NetPhos 2.0 software
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other morphological changes including disassembly of AJ,
increased migratory and invasive potential of cells in vitro,
activation of β-catenin signalling, increased expression of
vimentin, increased chemoresistance and decreased expres-
sion and nuclear translocation of E-cadherin [47]. Lastly, the
authors used immunohistochemistry to show that EPLIN
downregulation is correlated with cancer progression in mul-
tiple cancer models including lymph node metastasis in PCa,
where EPLIN expression was significantly reduced [47]. Al-
together, this illustrates that EPLIN may be involved in the
regulation of EMT and PCa progression and loss of EPLIN
can lead to diverse downstream cellular effects. EPLIN in PCa
has also been recently evaluated by our laboratory using the
classical PCa cell line, PC-3. By immunohistochemistry
(IHC), EPLIN displayed a significant decrease in staining
for tumour cells in comparison to normal (see Fig. 7a) [12].
This is accompanied by quantification of staining intensity
within the cohort, where lower levels of EPLIN staining are
associated with cancerous and higher-tumour-grade samples
(see Fig. 7c, d) [12]. Overexpression analysis of EPLINα
resulted in decreased growth rate in tumour cells in vitro,
along with reduced invasiveness and cell adhesion to the ex-
tracellular matrix (ECM) [12]. Mice injected with PC-3 cells
overexpressing EPLINα developed tumours at a markedly
decreased rate in comparison to control [12]. Furthermore,
cells overexpressing EPLINα displayed a greater staining pat-
tern for the focal adhesion targeting protein, paxillin, implying
that EPLIN may also be present at these plaques [4, 12]. Al-
together, these results demonstrate the potential of EPLIN for
monitoring PCa progression and how it can be manipulated to
suppress PCa via impeding cancerous traits.
3.2 Breast cancer
Our lab has recently evaluated EPLIN involvement in cancer
progression in a number of model systems [10–14]. By com-
paring EPLINα IHC staining in normal vs tumour cells in
breast cancer progression, EPLINα was found to be




Prostate cancer (1) Immunoblot analyses demonstrated that EPLIN expression in prostate cancer cell lines and xenograft tumours is
reduced compared to prostate epithelial cells (PcEC). PC-3, DU-145, LNCaP, LAPC4, LAPC3 and LAPC9 all
displayed loss of EPLIN protein.
(2) IHC analyses of normal and cancerous clinical prostate sections revealed a greatly reduced staining pattern of
EPLIN in tumour samples. Overexpression of EPLIN in PC-3 cells negatively impacted cell growth in vitro and
in vivo, and were less invasive and had reduced adhesion to the ECM.
(3) EPLIN is implicated in the process of EMT, and IHC analysis revealed that EPLIN loss is correlated with prostate
cancer progression, with a significant reduction of EPLIN expression in tissues with lymph node metastases





Breast cancer (1) Immunoblot analysis revealed reduced or abolished expression of EPLIN protein in tumourigenic breast cancer
cell lines (BT-20, SK-Br-3, MCF-7, T-47D and MDA-MB-231) compared to mammary epithelial cells (MEC),
immortalised mammary epithelial cells (IMEC) and a non-tumourigenic breast cancer cell line, HBL-100.
(2) Analysis by Q-PCR revealed lower levels of EPLINα in tumour samples compared to normal. Higher-tumour-
grade samples had lower EPLIN transcript. Patients with poorer prognosis and patients who died of the cancer had
significantly lower levels of EPLIN transcript. Overexpression of EPLIN rendered cells less invasive, and had a
reduced growth rate in vitro and in vivo and were less motile.
(3) IHC analyses displayed a reduction in EPLIN staining in tissues of breast cancer lymph node metastases compared






Q-PCR analyses revealed lower levels of EPLINα transcript in tumour tissues compared to normal. Higher-tumour-
grade samples had lower EPLIN transcript. Patients who died of the cancer had significantly lower levels of EPLIN
transcript. Patients with local advanced T stage cancer (T2–T4) and patients with lymphatic metastasis had lower
levels of EPLINα transcript. Overexpression analysis caused cells to be less invasive and to have a reduced growth rate




Q-PCR analyses revealed reduced levels of EPLINα transcript in tumour samples compared to normal. Tissues of a
higher TNM stage and where there was nodal involvement also had lower EPLIN transcript. Overexpression




IHC analyses revealed that EPLIN is significantly reduced in lymph node metastatic tumours compared to primary
tumours in colorectal cancer.
[47]
SCCHN IHC analyses revealed a reduction of EPLIN staining of cancerous tissue with lymph node metastasis compared to
primary tumours.
[47]
Oral cancer Northern analyses determined that EPLIN expression in 8/8 oral cancer cell lines is reduced compared to control
G3PDH.
[4]
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substantially weaker in tumour cells than in normal epithelial
cells (see Fig. 7b) [10]. This correlated with lower EPLINα
transcript in tumour samples compared to normal samples (see
Fig. 7e) with lower EPLIN levels being associated with higher
tumour grade, a poorer patient prognosis and reduced overall
survival rates (see Fig. 7f–h) [10]. IHC analyses in breast
cancer from additional research groups also show EPLIN loss
as the tumour becomes more aggressive, specifically compar-
ing EPLIN immunointensity of primary tumours vs tumours
with lymph node metastases [47]. Lastly, in vitro and in vivo
overexpression analysis of EPLIN highlighted significant re-
ductions in cell growth and cell invasion using transfected
Fig. 8 Proposed EPLIN signalling pathways and implications for loss in
cancer. When cancer is not present, EPLIN associates with the actin
cytoskeleton linking the cadherin–catenin complex to F-actin via interac-
tion with α-catenin. The signal transduction protein, paxillin, interacts
with EPLIN in the cytoplasm, and this complex likely stabilises actin
dynamics. ERK phosphorylates EPLIN regulating cell motility and mi-
gration. When cancer is present and EPLIN is lost, the actin cytoskeleton
becomes less organised and this induces membrane ruffling. Paxillin
targeting is likely lost reducing focal adhesion between the cadherin–
catenin complex and actin. These molecular, cellular and morphological
consequences may result in increased metastatic potential including en-
hanced cell migration and motility. Signalling pathways summarised
from [12, 16, 20, 47]. Image generated using Pathway Builder 2.0
software
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breast cancer cell lines, and also, highly significant reductions
in tumour size were observed in nude mice inoculated with
EPLIN-α-transfected vs control MDA-MB-231 breast cancer
cells [10].
3.3 Further pathological implications
Clinical implications for EPLIN also include oesophageal and
pulmonary cancer (Table 2). Q-PCR analysis displayed re-
duced expression of EPLINα in an oesophageal cancer cohort
for both cancerous tissue and cancer cell models [11]. With
regard to tumour histological grade, tumour–node–metastasis
(TNM) status, nodal status and survival status, EPLINα tran-
script generally decreased with levels significantly lower in
patients who ultimately died from the cancer, suggesting that
EPLINα is implicated in oesophageal cancer progression and
may give an indication for cancer prognosis [11]. Overexpres-
sion analysis of EPLINα in the KYSE150 cell line resulted in
decreased growth and invasiveness compared to normal, sug-
gesting that EPLINα has tumour-suppressive ability by regu-
lating cellular aggressiveness in oesophageal cancer [11]. In a
pulmonary cancer cohort also conducted by our lab, Q-PCR
analysis showed a reduction of EPLINα expression in tumour
vs normal samples, where EPLIN was also reduced in later
TNM stages and cancers with lymph node involvement [14].
Using the SKMES-1 cell line, overexpression of EPLINα via
transfection in the pEF6 expression vector inhibited cell
growth and cell motility [14]. In addition to the apparent mo-
lecular loss of EPLIN in various cancers, EPLIN also appears
to be reduced at the protein level for colorectal cancer and
squamous cell carcinoma of the head and neck (SCCHN),
where IHC analysis revealed that EPLIN is decreased in can-
cers with lymph node metastases vs primary tumours [47].
Collectively, these studies suggest EPLINmay be a clinical
indicator for cancer progression in addition to providing fur-
ther evidence of a tumour-suppressive role for EPLINα in the
regulation of cancer progression.
Finally, in addition to the implication of EPLIN in the
spread and progression of cancer, a recent publication pro-
vides a link between EPLIN and renal diseases where patients
with either membranoproliferative glomerulonephritis
(MPGN) or IgA nephropathy had a decreased expression pro-
file for EPLIN via IHC analysis [16]. This advocates the idea
that EPLIN may be involved in the pathology of various dis-
ease states.
3.4 Angiogenesis
Angiogenesis is the formation of new blood vessels from pre-
existing vessels and is essential for wound healing and normal
growth and development. The angiogenic process is frequent-
ly utilised by cancer cells, by a means of metastasis, to reach
secondary sites around the body and develop secondary
tumours. Angiogenesis is therefore a critical factor when
targeting cancer therapies. EPLINα demonstrates a suppres-
sive role in angiogenesis, where overexpression analysis in the
HECV endothelial cell line resulted in a reduced capacity to
generate tubular structures in a Matrigel tubule formation as-
say when compared to vector controls [13]. This regulatory
effect was also apparent in vivo where mice injected with
HECV cells overexpressing EPLINα in conjunction with can-
cer cells developed tumours significantly slower than controls
[13]. Forced expression also appears to exert an effect on cell
matrix adhesion and migration capabilities in this cell line
where cells overexpressing EPLINα both migrated at a sig-
nificantly slower rate and were significantly less able to ad-
here to the Matrigel basement membrane [13]. This suppres-
sive role in angiogenesis illustrates that EPLINα has poten-
tially various regulatory mechanisms for reducing cancer me-
tastasis and could be an effective target for cancer therapy.
4 Conclusions and outlook
The interaction of EPLIN and actin has provided an excellent
model for investigating multiple aspects of cancer progression
over the last decade. The discovery of EPLIN led to a subtle
paradigm shift in structural view and organisation of cytoskel-
etal dynamics, with the acknowledgment that various actin-
related molecules contribute to multiple dynamic processes
underlying cellular migration and invasion. There is an
established link between EPLIN and cancer progression with
frequent downregulation of EPLIN in more aggressive cell
lines, reduced staining in cancerous tissue samples and re-
duced growth potentials when there is forced expression of
the EPLINα isoform in vitro and in vivo. EPLIN is function-
ally linked to molecules like actin and paxillin and has been
implicated in a number of potential pathways to enhance met-
astatic potential (outlined in Fig. 8). However, the precise
mechanistic action of EPLIN and, subsequently, how EPLIN
loss contributes to the development of cancer remain elusive.
Mechanistic investigations will therefore be crucial to eluci-
date the full importance of EPLIN in cancer pathophysiology.
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